BGP-15 has shown a highly promising profile in animal models
of metabolic and cardiovascular physiology and disease:
- Increases insulin sensitivity and improves glucose
utilization
- Efficacy is comparable to that of rosiglitazone and
metformin
- Synergistically enhances the efficacy of oral
anti-diabetic agents
- Prevents insulin resistance and weight gain, induced by
anti-schizophrenic drugs
- Shows beneficial effect of NO-mediated vaso-relaxation
- Results in protection of mitochondria, induces
mitochondrial biogenesis
These scientific data fully support the sought product
profile of BGP-15 as an anti-diabetic drug with added
cardiovascular and metabolic benefits.
